Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer.
Elicio Therapeutics has raised $15.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2026.
Elicio Therapeutics's investors include EFung Capital, Angion, GKCC, Thynk Capital, Trend Investment Group.
Elicio Therapeutics is headquartered in Cambridge, United States.
Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer.
Elicio Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Elicio Therapeutics — Funding & Investors." VCBacked, July 2, 2026, https://www.vcbacked.co/company/elicio-therapeutics. Accessed August 14, 2026.
VCBacked. (2026). Elicio Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/elicio-therapeutics
{{cite web |title=Elicio Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/elicio-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated